ChalmersJRWojnarowskaFKirtschigG, et al.(2017) A randomised controlled trial to compare the safety, effectiveness and cost effectiveness of doxycycline (200 mg/day) with oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: The Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial. Health Technology Assessment21(10): 1–90. DOI: 10.3310/hta21100.
2.
HubnerFLanganEAReckeA (2019) Lichen planus pemphigoides: From lichenoid inflammation to autoantibody-mediated blistering. Frontiers in Immunology10: 1389–DOI: 10.3389/fimmu.2019.01389.
3.
LanganSMSmeethLHubbardR, et al.(2008) Bullous pemphigoid and pemphigus vulgaris – incidence and mortality in the UK: Population based cohort study. British Medical Journal337: 1–7. DOI: 10.1136/bmj.a180.
4.
LinLHwangBJCultonDA, et al.(2018) Eosinophils mediate tissue injury in the autoimmune skin disease bullous pemphigoid. Journal of Investigative Dermatology138(5): 1032–1043. DOI: 10.1016/j.jid.2017.11.031.
5.
MiyamotoDSantiCGAokiV, et al.(2019) Bullous pemphigoid. Anais Brasileiros de Dermatologia94(2): 133–146.
VenningVATaghipourKMohd MustapaMF, et al.(2012) British Association of Dermatologists’ guidelines for the management of bullous pemphigoid 2012. British Journal of Dermatology167(6): 1200–1214. DOI: 10.1111/bjd.12072.
